Merit has announced the start of work on the Moderna Innovation and Technology Centre (MITC) in Harwell, Oxfordshire.

The MITC will encompass research, development, and a manufacturing facility, which aims to provide increased access to mRNA vaccines for a wide range of respiratory diseases, pending independent regulatory assessment and licensure.  

Tony Wells, CEO at Merit, said: “We are delighted to be working collaboratively with yet another leading global biotechnology company. Our innovative approach and product-based solution will deliver the project at speed, leveraging the efficiencies and improved productivity.  

"Technically complex projects of this size and scale are always exciting, they also act as a testament to the reputation of Merit and the excellence of what we deliver. This is the future of construction in action, bringing enormous advantages in terms of quality and speed and, in turn, playing a role in delivering vital vaccines to the UK public."